CVKD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cadrenal Therapeutics Inc (CVKD) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks clear bullish signals, has weak financial performance, and no significant positive catalysts. Holding off on this investment until more favorable conditions arise would be prudent.
The technical indicators show a bearish trend with MACD below 0 and negatively contracting, RSI in the neutral zone at 46.651, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 4.983, with key support at 4.322 and resistance at 5.644.
The company has completed its End-of-Phase 2 meeting with the FDA for CAD-1005, aligning on a Phase 3 registrational path. Analyst maintains a Buy rating despite lowering the price target.
The stock has shown weak financial performance with no revenue growth, a significant drop in net income (-27.42% YoY), and a sharp decline in EPS (-43.92% YoY). Additionally, there is no recent news, no significant insider or hedge fund trading activity, and no recent congress trading data.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income drop to -3,038,990 (-27.42% YoY), and a decline in EPS to -1.43 (-43.92% YoY). Gross margin remains at 0%.
H.C. Wainwright lowered the price target from $32 to $13 due to updated share count and financing needs. However, the analyst maintains a Buy rating, citing progress on CAD-1005.
